维普中文期刊产品整合服务
6篇 您的检索式:作者名="Qiangling Sun"
    题名 作者 年代 出处 被引量
1The efficiency and toxicity of dodecafluoro-2-methylpentan-3-one in suppressing lithium-ion battery fire显示文摘Currently,the effective and clean suppression of lithium-ion battery(LIB)fires remains a challenge.The present work investigates the use of various inhibitor doses(Xin)of dodecafluoro-2-methylpentan-3-one(C_(6) F_(12)O)in 300 Ah LIBs,and systematically examines the thermal and toxic hazards of the extinguished batteries via real scale combustion and gas analysis.The inhibitor is shown to be completely effective.The inhibition mechanism involves a combination of chemical inhibition and physical cooling.While the chemical inhibition effect tends to saturate with increasing Xin,the physical cooling remains effective at higher inhibitor doses.However,extinguishing the battery fire with a high Xin of C_(6)F_(12)O is found to incur serious toxicity problems.These results are expected to provide a guideline for the design of inhibitor doses for the suppression of LIB fires.Yujun Liu Kai Yang Mingjie Zhang Shi Li Fei Gao Qiangling Duan Jinhua Sun Qingsong Wang 2022Journal of Energy Chemistry2022,31,2:10
2Downregulation of LINC01296 suppresses non-small-cell lung cancer via targeting miR-143-3p/ATG2B显示文摘The 5-year survival rate of lung cancer is one of the lowest among various malignant tumors.Long noncoding RNAs(lncRNAs),noncoding RNAs longer than 200 nucleotides,can function either as tumor suppressors or as oncogenes.The aim of this study is to investigate the function of lncRNA LINC01296 and its molecular mechanism in non-small-cell lung cancer(NSCLC).According to the Gene Expression Omnibus database,10 differentially expressed lncRNAs in NSCLC cells and patient tissues are upregulated.LINC01296 is the one with the most significant overexpression.Knockdown of LINC01296 inhibits the growth and migration,arrests the cell cycle,and promotes the apoptosis of NSCLC cells.Knocking down LINC01296 in vivo suppresses tumor growth and metastasis.LINC01296 also acts as the sponge of miR-143-3p.Lowering the expression of LINC01296 leads to decreased expression of autophagy-related 2B,ATG2B,a target gene of miR-143-3p.Moreover,downregulation of LINC01296 promotes paclitaxel sensitivity in NSCLC.These results demonstrated that the LINC01296/miR-143-3p/ATG2B axis is crucial in promoting the development of NSCLC and paclitaxel resistance.Our study may provide new ideas for the further research of clinical chemotherapy of NSCLC in the near future.Yanli Li Hui Zhang Jing Guo Wanqiu Li Xianyi Wang Caiyan Zhang Qiangling Sun Zhongliang Ma 2021Acta Biochimica et Biophysica Sinica2021,53,12:8
3Hemorrhagic Fever with Renal Syndrome — Liaoning Province, China, 1999−2018显示文摘Summary What is already known on this topic?Hemorrhagic fever with renal syndrome(HFRS)is endemic in Liaoning Province.Both Seoul and Hantaan virus are circulating in rodents,and epidemic outbreaks and sporadic cases have been recorded every year since the disease was recognized.Cui Shang Yingwei Sun Qiangling Yin Xiaoxia Huang Xuesheng Liu Quanfu Zhang Lingling Mao Chuan Li Aqian Li Qin Wang Lina Sun Mifang Liang Shiwen Wang Dexin Li Jiandong Li 2020China CDC weekly2020,2,20:6
4Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants显示文摘Multiple new variants of severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)have constantly emerged,as the delta and omicron variants,which have developed resistance to currently gained neutralizing antibodies.This highlights a critical need to discover new therapeutic agents to overcome the variants mutations.Despite the availability of vaccines against coronavirus disease 2019(COVID-19),the use of broadly neutralizing antibodies has been considered as an alternative way for the prevention or treatment of SARS-Co V-2 variants infection.Here,we show that the nasal delivery of two previously characterized broadly neutralizing antibodies(F61 and H121)protected K18-h ACE2 mice against lethal challenge with SARS-Co V-2 variants.The broadly protective efficacy of the F61 or F61/F121 cocktail antibodies was evaluated by lethal challenge with the wild strain(WIV04)and multiple variants,including beta(B.1.351),delta(B.1.617.2),and omicron(B.1.1.529)at 200or 1000 TCID_(50),and the minimum antibody administration doses(5-1.25 mg/kg body weight)were also evaluated with delta and omicron challenge.Fully prophylactic protections were found in all challenged groups with both F61 and F61/H121 combination at the administration dose of 20 mg/kg body weight,and corresponding mice lung viral RNA showed negative,with almost all alveolar septa and cavities remaining normal.Furthermore,low-dose antibody treatment induced significant prophylactic protection against lethal challenge with delta and omicron variants,whereas the F61/H121 combination showed excellent results against omicron infection.Our findings indicated the potential use of broadly neutralizing monoclonal antibodies as prophylactic and therapeutic agent for protection of current emerged SARS-Co V-2 variants infection.Jia Lu Qiangling Yin Rongjuan Pei Qiu Zhang Yuanyuan Qu Yongbing Pan Lina Sun Ding Gao Cuiqin Liang Jingwen Yang Wei Wu Jiandong Li Zongqiang Cui Zejun Wang Xinguo Li Dexin Li Shiwen Wang Kai Duan Wuxiang Guan Mifang Liang Xiaoming Yang 2022Virologica Sinica2022,37,2:4
5Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants显示文摘Severe acute respiratory syndrome coronavirus 2(SARS-Co V-2)has precipitated multiple variants resistant to therapeutic antibodies.In this study,12 high-affinity antibodies were generated from convalescent donors in early outbreaks using immune antibody phage display libraries.Of them,two RBD-binding antibodies(F61 and H121)showed high-affinity neutralization against SARS-Co V-2,whereas three S2-target antibodies failed to neutralize SARS-Co V-2.Following structure analysis,F61 identified a linear epitope located in residues G446–S494,which overlapped with angiotensinconverting enzyme 2(ACE2)binding sites,while H121 recognized a conformational epitope located on the side face of RBD,outside from ACE2 binding domain.Hence the cocktail of the two antibodies achieved better performance of neutralization to SARS-Co V-2.Importantly,these two antibodies also showed efficient neutralizing activities to the variants including B.1.1.7 and B.1.351,and reacted with mutations of N501 Y,E484 K,and L452 R,indicated that it may also neutralize the recent India endemic strain B.1.617.The unchanged binding activity of F61 and H121 to RBD with multiple mutations revealed a broad neutralizing activity against variants,which mitigated the risk of viral escape.Our findings revealed the therapeutic basis of cocktail antibodies against constantly emerging SARS-Co V-2 variants and provided promising candidate antibodies to clinical treatment of COVID-19 patients infected with broad SARS-Co V-2 variants.Yuanyuan Qu Xueyan Zhang Meiyu Wang Lina Sun Yongzhong Jiang Cheng Li Wei Wu Zhen Chen Qiangling Yin Xiaolin Jiang Yang Liu Chuan Li Jiandong Li Tianlei Ying Dexin Li Faxian Zhan Youchun Wang Wuxiang Guan Shiwen Wang Mifang Liang 2021Virologica Sinica2021,36,5:3
6Over-expression of miR-125a-5p inhibits proliferation in C2C12 myoblasts by targeting E2F3显示文摘MicroRNAs miRNAs 是在长度的 2025 核苷酸的小非编码的 RNA 的一个班。miRNAs 在房间的许多类型的增长起重要作用,这被显示出,包括 myoblasts。在这研究,我们使用了即时量的聚合酶链反应,西方的弄污,在 C2C12 myoblasts 的增长期间探索 miR-125a-5p 的角色的 EdU,流动 cytometry,和 CCK-8 试金。miR-125a-5p 的表示在 C2C12 myoblast 增长期间被减少,这被发现。miR-125a-5p 的在表示上禁止了由 EdU 染色,流动 cytometry,和 CCK8 试金显示了的 C2C12 myoblast 增长。miR-125a-5p 能否定地在 posttranscriptional 水平调整 E2F3 表示,这也被发现,经由在 3 untranslated 区域的一个特定的目标地点。显示出的 E2F3 击倒 C2C12 myoblast 增长上的类似的禁止的效果。因此,我们的调查结果建议 miR-125a-5p 可以由指向 E2F3 充当 C2C12 myoblast 增长的一个否定管理者。Chengchuang Song Guofang Wu Aoqi Xiang Qiangling Zhang Wanhua Li Gongshe Yang Xin'e Shi Shiduo Sun Xiao Li 2015Acta Biochimica et Biophysica Sinica2015,47,4:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费